ClearSight Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering its eye-drop formulation technology. The application includes 26 claims related to formulations containing quaternary chitosan derivatives, which showed stability and preserved antiviral activity in testing described in the patent application. This milestone moves the company closer to securing U.S. patent protection for its technology as it continues developing new eye-care products.
